EXEL
Price
$36.65
Change
-$0.39 (-1.05%)
Updated
Apr 3, 02:37 PM (EDT)
Capitalization
10.37B
40 days until earnings call
SRPT
Price
$58.83
Change
-$3.64 (-5.83%)
Updated
Apr 3, 04:06 PM (EDT)
Capitalization
6.06B
27 days until earnings call
Ad is loading...

EXEL vs SRPT

Header iconEXEL vs SRPT Comparison
Open Charts EXEL vs SRPTBanner chart's image
Exelixis
Price$36.65
Change-$0.39 (-1.05%)
Volume$888
Capitalization10.37B
Sarepta Therapeutics
Price$58.83
Change-$3.64 (-5.83%)
Volume$6.04K
Capitalization6.06B
EXEL vs SRPT Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. SRPT commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and SRPT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (EXEL: $37.04 vs. SRPT: $62.47)
Brand notoriety: EXEL and SRPT are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 70% vs. SRPT: 229%
Market capitalization -- EXEL: $10.37B vs. SRPT: $6.06B
EXEL [@Biotechnology] is valued at $10.37B. SRPT’s [@Biotechnology] market capitalization is $6.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 3 TA indicator(s) are bullish while SRPT’s TA Score has 4 bullish TA indicator(s).

  • EXEL’s TA Score: 3 bullish, 4 bearish.
  • SRPT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SRPT is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а +0.08% price change this week, while SRPT (@Biotechnology) price change was -14.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.84%. For the same industry, the average monthly price growth was -9.88%, and the average quarterly price growth was -14.17%.

Reported Earning Dates

EXEL is expected to report earnings on May 13, 2025.

SRPT is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-7.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.4B) has a higher market cap than SRPT($6.06B). SRPT has higher P/E ratio than EXEL: SRPT (26.70) vs EXEL (21.05). EXEL YTD gains are higher at: 11.231 vs. SRPT (-48.622). EXEL has higher annual earnings (EBITDA): 719M vs. SRPT (317M). SRPT has more cash in the bank: 1.36B vs. EXEL (1.11B). EXEL has less debt than SRPT: EXEL (191M) vs SRPT (1.34B). EXEL has higher revenues than SRPT: EXEL (2.17B) vs SRPT (1.9B).
EXELSRPTEXEL / SRPT
Capitalization10.4B6.06B172%
EBITDA719M317M227%
Gain YTD11.231-48.622-23%
P/E Ratio21.0526.7079%
Revenue2.17B1.9B114%
Total Cash1.11B1.36B82%
Total Debt191M1.34B14%
FUNDAMENTALS RATINGS
EXEL vs SRPT: Fundamental Ratings
EXEL
SRPT
OUTLOOK RATING
1..100
6960
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
22100
SMR RATING
1..100
4046
PRICE GROWTH RATING
1..100
4195
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRPT's Valuation (70) in the Biotechnology industry is in the same range as EXEL (76). This means that SRPT’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for SRPT (100). This means that EXEL’s stock grew significantly faster than SRPT’s over the last 12 months.

EXEL's SMR Rating (40) in the Biotechnology industry is in the same range as SRPT (46). This means that EXEL’s stock grew similarly to SRPT’s over the last 12 months.

EXEL's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for SRPT (95). This means that EXEL’s stock grew somewhat faster than SRPT’s over the last 12 months.

EXEL's P/E Growth Rating (90) in the Biotechnology industry is in the same range as SRPT (100). This means that EXEL’s stock grew similarly to SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELSRPT
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 15 days ago
65%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 7 days ago
62%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
66%
View a ticker or compare two or three
Ad is loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPYG81.620.67
+0.83%
SPDR® Portfolio S&P 500 Growth ETF
KNCT101.550.53
+0.53%
Invesco Next Gen Connectivity ETF
JEMA38.530.04
+0.10%
JPMorgan ActiveBuilders EM Eq ETF
FLKR18.61-0.03
-0.16%
Franklin FTSE South Korea ETF
EDD4.74-0.02
-0.42%
Morgan Stanley Emerging Markets Domestic Debt Fund

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.79%
SRPT - EXEL
36%
Loosely correlated
+0.90%
ALNY - EXEL
34%
Loosely correlated
+4.33%
TECH - EXEL
33%
Poorly correlated
+1.80%
MRSN - EXEL
32%
Poorly correlated
+1.68%
ORMP - EXEL
32%
Poorly correlated
+3.29%
More